Provided by Tiger Trade Technology Pte. Ltd.

Adagene

4.02
-0.0700-1.71%
Post-market: 4.020.00000.00%19:30 EDT
Volume:61.31K
Turnover:246.91K
Market Cap:269.92M
PE:-10.65
High:4.12
Open:4.11
Low:3.97
Close:4.09
52wk High:4.85
52wk Low:1.30
Shares:67.14M
Float Shares:58.88M
Volume Ratio:0.15
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3773
EPS(LYR):-0.3750
ROE:-28.50%
ROA:-13.95%
PB:3.02
PE(LYR):-10.72

Loading ...

Adagene adds Third Arc Bio CEO Peter Lebowitz to advisory board

Reuters
·
Apr 14

Press Release: Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Dow Jones
·
Apr 14

New Adagene Immuno‑Oncology Tie‑Up Could Be A Game Changer For Incyte (INCY)

Simply Wall St.
·
Apr 13

Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program

TIPRANKS
·
Apr 06

Adagene Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 06

Adagene price target raised to $10 from $9 at Guggenheim

TIPRANKS
·
Apr 06

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires Live
·
Apr 02

Adagene Drug Shows Stronger Tumor Response at Higher Dose in Early Cancer Trial

Dow Jones
·
Apr 02

Adagene 18.666M share Spot Secondary priced at $3.75

TIPRANKS
·
Apr 02

Adagene enters pact with Incyte for combination of muzastotug, INCA33890

TIPRANKS
·
Apr 02

Adagene announces results from the latest data cut of muzastotug study

TIPRANKS
·
Apr 02

Adagene Prices $70 Million ADS Public Offering

MT Newswires Live
·
Apr 02

Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer

TIPRANKS
·
Apr 02

Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline

TIPRANKS
·
Apr 02

Adagene prices follow-on offering at USD 70 million, ADSs at USD 3.75

Reuters
·
Apr 02

Adagene, Incyte partner to test muzastotug combo in MSS colorectal cancer trial

Reuters
·
Apr 02

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

GlobeNewswire
·
Apr 02

Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028

TIPRANKS
·
Apr 02

Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate

Benzinga Earnings
·
Apr 02

Adagene reports FY25 EPS (24c) vs (51c) last year

TIPRANKS
·
Apr 02